news Scientists explore CA2 neuron mitochondria for memory loss targets 10 November 2021 | By Anna Begley (Drug Target Review) The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
news Researchers achieve DNA methylation removal in mouse models 9 November 2021 | By Anna Begley (Drug Target Review) The study showed that DNA “de-methylation” activity can be targeted to anywhere in the DNA and may be a new therapeutic strategy.
news MicroRNA in red blood cells causes vascular damage in type 2 diabetes 9 November 2021 | By Anna Begley (Drug Target Review) Researchers discovered that cardiovascular damage was caused by reduced microRNA-210 levels in patient cells and mice with type 2 diabetes.
news IL-36Ra discovery may help heal skin wounds from ischemia reperfusion 8 November 2021 | By Anna Begley (Drug Target Review) The absence of interleukin-36 receptor antagonist (IL-36Ra) significantly slowed down wound healing in ischemia-reperfusion injuries in mice.
news ABI3 gene may be the key to new Alzheimer’s disease therapies 8 November 2021 | By Anna Begley (Drug Target Review) The study found that deleting the ABI3 gene in mice increased plaques and inflammation in the brain, suggesting avenues for new treatments.
news Researchers identify RNA molecule that suppresses prostate tumours 8 November 2021 | By Anna Begley (Drug Target Review) Scientists discover a long noncoding RNA, termed NXTAR, and a small molecule drug that could be used to treat prostate cancer.
news Tropical frog models reveal novel kidney disease insights 5 November 2021 | By Anna Begley (Drug Target Review) Scientists utilised CRISPR technology and deep learning systems to investigate the genes associated with polycystic kidney disease.
news New class of CAR T cells combat previously “untargetable” cancer drivers 4 November 2021 | By Anna Begley (Drug Target Review) The peptide-centric chimeric antigen receptors killed neuroblastoma cells in mice and could potentially expand the pool of immunotherapeutic targets.
news Alterity’s ATH434 improves Parkinson’s-related gastrointestinal dysfunction 4 November 2021 | By Anna Begley (Drug Target Review) ATH434 reversed some of the gastrointestinal damage to the enteric nervous system associated with Parkinson's disease in a pre-clinical study.
news Experimental drug boosts immunotherapy efficacy for pancreatic cancer 4 November 2021 | By Anna Begley (Drug Target Review) An experimental drug enhanced the benefit of immunotherapy, reducing and in some cases eliminating pancreatic cancer in mice.
news Gene therapy bolsters Parkinson’s drug benefits in pre-clinical study 3 November 2021 | By Anna Begley (Drug Target Review) The gene therapy restored the ability of neurons to convert levodopa to dopamine and may help develop therapies to slow disease progression.
news Moderna and Metagenomi to develop in vivo gene therapies 3 November 2021 | By Anna Begley (Drug Target Review) Moderna and Metagenomi have announced a collaboration to jointly create next-generation in vivo gene editing therapeutics.
news Monoclonal antibodies prevent COVID-19 inflammation in macaques 2 November 2021 | By Anna Begley (Drug Target Review) Neutralising monoclonal antibodies protected aged macaque monkeys from SARS-CoV-2 and reduced inflammation, including in cerebrospinal fluid, a new study has shown.
news Pathway and enzyme responsible for CKD thrombosis identified 2 November 2021 | By Anna Begley (Drug Target Review) Scientists have discovered a novel pathway and enzyme that causes thrombosis in chronic kidney disease (CKD) patients, indicating a new drug target.
news GLP-1 and GIP receptor agonists reduce mouse obesity in pre-clinical study 1 November 2021 | By Anna Begley (Drug Target Review) Treatment with Viking Therapeutics' dual agonists resulted in mean reductions in body weight of up to 27 percent compared to semaglutide-treated animals.
